Block Drug's BC Powder
Company will met with FDA at a May 19 OTC "feedback meeting" to discuss contribution of the adjuvant salicylamide to Block's analgesic product, which also contains aspirin and caffeine. Salicylamide, along with other adjuvants, are classified as Category III in analgesic TFM. Block gave agency a pharmacokinetic study to show that ingredient increases the plasma concentration of aspirin, and a protocol for a study on salicylamide's role in reducing pain to support moving the ingredient to Category I. The meeting will be held at 2:30 in Conference Room C of FDA's Parklawn Building.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.